ClinicalTrials.Veeva

Menu
E

Excell Research, Inc | Oceanside, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atogepant
Lurasidone
Rapastinel
Cariprazine
KarXT
Eszopiclone
ABBV-932
Armodafinil
Seltorexant
JNJ-42847922

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

21 of 122 total trials

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (APPROACH)

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in part...

Enrolling
Major Depressive Disorder
Behavioral: Psychological Support
Drug: CYB003

This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Not yet enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel....

Enrolling
Major Depressive Disorder
Drug: Zelquistinel

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Placebo
Drug: Azetukalner

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompa...

Enrolling
Chronic Migraine
Drug: Atogepant
Drug: Placebo for Atogepant

The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive sym...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Seltorexant

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Active, not recruiting
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Icalcaprant
Drug: Placebo for Icalcaprant

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Placebo-Matching Atogepant
Drug: Atogepant

This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with plac...

Enrolling
Migraine
Drug: Placebo
Drug: Elismetrep

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD.Eligible participants will enter a 4-week Treatment Period where the...

Enrolling
Post Traumatic Stress Disorder
Drug: Placebo
Drug: TSND-201

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Invitation-only
Major Depressive Disorder
Drug: Azetukalner

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only
Migraine Prophylaxis
Drug: Atogepant

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irrita...

Enrolling
Irritability Associated With Autism Spectrum Disorder
Drug: Lumateperone high dose
Drug: Lumateperone low dose

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophren...

Enrolling
Autism Spectrum Disorder
Schizophrenia
Drug: Lumateperone

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling
Generalized Anxiety Disorder (GAD)
Drug: Antidepressant Therapy (ADT)
Drug: ABBV-932

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Trial sponsors

AbbVie logo
Sumitomo Pharma logo
Allergan logo
Janssen (J&J Innovative Medicine) logo
Otsuka logo
Allergan logo
K
Tonix Pharmaceuticals logo
Astellas logo
Biogen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems